Microbial paclitaxel: advances and perspectives

Area of Science:

• Biotechnology
• Microbiology
• Pharmacology

Background:

• Paclitaxel (Taxol) is a crucial chemotherapy drug derived from natural sources.
• Microorganisms, particularly fungi, have been explored for paclitaxel production for over 15 years.
• Current production methods face environmental and cost challenges.

Purpose of the Study:

• To review the current state of research on microbial paclitaxel production.
• To assess the progress in developing heterologous paclitaxel biosynthesis pathways.
• To analyze the feasibility and future prospects of microbial fermentation for paclitaxel manufacturing.

Main Methods:

• Literature review of studies on paclitaxel-producing microorganisms.
• Analysis of research on genetic engineering and metabolic pathway reconstruction for heterologous production.
• Evaluation of challenges and opportunities in scaling up microbial fermentation processes.

Main Results:

• Numerous microorganisms capable of producing paclitaxel have been identified.
• Significant advancements have been made in understanding and engineering paclitaxel biosynthesis pathways.
• Challenges remain in achieving commercially viable yields and efficient downstream processing.

Conclusions:

• Microbial fermentation presents a sustainable alternative for paclitaxel production.
• Further research in synthetic biology and metabolic engineering is crucial for commercial success.
• Heterologous biosynthesis holds significant promise for cost-effective and scalable paclitaxel manufacturing.